Andres Y. Maldonado
Stock Analyst at H.C. Wainwright
(4.83)
# 428
Out of 4,382 analysts
290
Total ratings
43.9%
Success rate
30.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $40 | $17.34 | +130.68% | 9 | Jun 3, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $40 | $7.56 | +429.10% | 17 | Jun 2, 2026 | |
| IBRX ImmunityBio | Reiterated: Buy | $15 | $6.92 | +116.76% | 25 | Jun 2, 2026 | |
| MNPR Monopar Therapeutics | Reiterated: Buy | $105 | $59.78 | +75.64% | 9 | Jun 2, 2026 | |
| CADL Candel Therapeutics | Maintained: Buy | $23 | $8.51 | +170.27% | 12 | Jun 2, 2026 | |
| IMNM Immunome | Reiterated: Buy | $40 | $18.58 | +115.29% | 5 | Jun 1, 2026 | |
| VSTM Verastem | Maintained: Buy | $18 | $3.71 | +385.18% | 6 | May 26, 2026 | |
| STRO Sutro Biopharma | Maintained: Buy | $50 | $26.09 | +91.64% | 11 | May 26, 2026 | |
| NBP NovaBridge Biosciences | Maintained: Buy | $9 | $1.65 | +447.11% | 12 | May 26, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Maintained: Buy | $10 | $3.66 | +173.22% | 12 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $6.63 | +261.99% | 8 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $4.16 | +549.04% | 16 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 | $53.72 | +86.15% | 25 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $10.30 | +94.17% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $11.97 | +67.08% | 19 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 → $65 | $44.30 | +46.73% | 30 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $3.73 | +248.53% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $6 | $1.64 | +265.85% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.9819 | +612.90% | 9 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $4 | $0.3923 | +919.63% | 27 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $5.58 | n/a | 11 | Nov 11, 2024 |
Syndax Pharmaceuticals
Jun 3, 2026
Reiterated: Buy
Price Target: $40
Current: $17.34
Upside: +130.68%
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Reiterated: Buy
Price Target: $40
Current: $7.56
Upside: +429.10%
ImmunityBio
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $6.92
Upside: +116.76%
Monopar Therapeutics
Jun 2, 2026
Reiterated: Buy
Price Target: $105
Current: $59.78
Upside: +75.64%
Candel Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $23
Current: $8.51
Upside: +170.27%
Immunome
Jun 1, 2026
Reiterated: Buy
Price Target: $40
Current: $18.58
Upside: +115.29%
Verastem
May 26, 2026
Maintained: Buy
Price Target: $18
Current: $3.71
Upside: +385.18%
Sutro Biopharma
May 26, 2026
Maintained: Buy
Price Target: $50
Current: $26.09
Upside: +91.64%
NovaBridge Biosciences
May 26, 2026
Maintained: Buy
Price Target: $9
Current: $1.65
Upside: +447.11%
Zentalis Pharmaceuticals
May 26, 2026
Maintained: Buy
Price Target: $10
Current: $3.66
Upside: +173.22%
May 26, 2026
Maintained: Buy
Price Target: $24
Current: $6.63
Upside: +261.99%
May 20, 2026
Reiterated: Buy
Price Target: $27
Current: $4.16
Upside: +549.04%
May 18, 2026
Maintained: Buy
Price Target: $100
Current: $53.72
Upside: +86.15%
May 15, 2026
Reiterated: Buy
Price Target: $20
Current: $10.30
Upside: +94.17%
May 12, 2026
Reiterated: Buy
Price Target: $20
Current: $11.97
Upside: +67.08%
May 8, 2026
Reiterated: Buy
Price Target: $58 → $65
Current: $44.30
Upside: +46.73%
May 8, 2026
Reiterated: Buy
Price Target: $13
Current: $3.73
Upside: +248.53%
May 8, 2026
Reiterated: Buy
Price Target: $25 → $6
Current: $1.64
Upside: +265.85%
May 6, 2026
Reiterated: Buy
Price Target: $7
Current: $0.9819
Upside: +612.90%
Dec 19, 2025
Reiterated: Buy
Price Target: $10 → $4
Current: $0.3923
Upside: +919.63%
Nov 11, 2024
Reiterated: Buy
Price Target: $4
Current: $5.58
Upside: n/a